Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/POR_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/POR_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/POR_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/POR_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/POR_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/POR_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005134612 | Liver | Cirrhotic | negative regulation of hydrolase activity | 139/4634 | 379/18723 | 1.24e-07 | 3.42e-06 | 139 |
GO:004343412 | Liver | Cirrhotic | response to peptide hormone | 149/4634 | 414/18723 | 1.70e-07 | 4.49e-06 | 149 |
GO:006201212 | Liver | Cirrhotic | regulation of small molecule metabolic process | 124/4634 | 334/18723 | 2.74e-07 | 6.79e-06 | 124 |
GO:003428412 | Liver | Cirrhotic | response to monosaccharide | 90/4634 | 225/18723 | 2.87e-07 | 7.01e-06 | 90 |
GO:007137511 | Liver | Cirrhotic | cellular response to peptide hormone stimulus | 110/4634 | 290/18723 | 3.73e-07 | 8.82e-06 | 110 |
GO:00431546 | Liver | Cirrhotic | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 40/4634 | 78/18723 | 4.00e-07 | 9.39e-06 | 40 |
GO:001095111 | Liver | Cirrhotic | negative regulation of endopeptidase activity | 98/4634 | 252/18723 | 4.19e-07 | 9.77e-06 | 98 |
GO:00435431 | Liver | Cirrhotic | protein acylation | 95/4634 | 243/18723 | 4.73e-07 | 1.07e-05 | 95 |
GO:001046612 | Liver | Cirrhotic | negative regulation of peptidase activity | 100/4634 | 262/18723 | 8.90e-07 | 1.84e-05 | 100 |
GO:20001177 | Liver | Cirrhotic | negative regulation of cysteine-type endopeptidase activity | 42/4634 | 86/18723 | 1.14e-06 | 2.31e-05 | 42 |
GO:190165311 | Liver | Cirrhotic | cellular response to peptide | 129/4634 | 359/18723 | 1.23e-06 | 2.49e-05 | 129 |
GO:00182051 | Liver | Cirrhotic | peptidyl-lysine modification | 134/4634 | 376/18723 | 1.29e-06 | 2.59e-05 | 134 |
GO:000974612 | Liver | Cirrhotic | response to hexose | 86/4634 | 219/18723 | 1.30e-06 | 2.59e-05 | 86 |
GO:009730512 | Liver | Cirrhotic | response to alcohol | 96/4634 | 253/18723 | 1.97e-06 | 3.65e-05 | 96 |
GO:003286911 | Liver | Cirrhotic | cellular response to insulin stimulus | 80/4634 | 203/18723 | 2.55e-06 | 4.63e-05 | 80 |
GO:001921611 | Liver | Cirrhotic | regulation of lipid metabolic process | 119/4634 | 331/18723 | 3.05e-06 | 5.39e-05 | 119 |
GO:00064751 | Liver | Cirrhotic | internal protein amino acid acetylation | 65/4634 | 160/18723 | 6.66e-06 | 1.04e-04 | 65 |
GO:00183931 | Liver | Cirrhotic | internal peptidyl-lysine acetylation | 64/4634 | 158/18723 | 8.75e-06 | 1.29e-04 | 64 |
GO:007054211 | Liver | Cirrhotic | response to fatty acid | 32/4634 | 64/18723 | 1.13e-05 | 1.60e-04 | 32 |
GO:000610911 | Liver | Cirrhotic | regulation of carbohydrate metabolic process | 70/4634 | 178/18723 | 1.14e-05 | 1.62e-04 | 70 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
POR | SNV | Missense_Mutation | | c.1987G>A | p.Asp663Asn | p.D663N | P16435 | protein_coding | tolerated(0.23) | benign(0.009) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
POR | SNV | Missense_Mutation | rs781866008 | c.838N>A | p.Asp280Asn | p.D280N | P16435 | protein_coding | deleterious(0.03) | benign(0.41) | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
POR | SNV | Missense_Mutation | rs782053091 | c.709N>A | p.Glu237Lys | p.E237K | P16435 | protein_coding | deleterious(0.05) | benign(0.182) | TCGA-BH-A0AU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
POR | SNV | Missense_Mutation | novel | c.893N>A | p.Gly298Glu | p.G298E | P16435 | protein_coding | deleterious(0.01) | benign(0.376) | TCGA-GM-A3NY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
POR | insertion | Frame_Shift_Ins | novel | c.937_938insG | p.Ser313CysfsTer6 | p.S313Cfs*6 | P16435 | protein_coding | | | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR |
POR | insertion | Nonsense_Mutation | novel | c.938_939insTTGAACCTGGGAGG | p.Lys314Ter | p.K314* | P16435 | protein_coding | | | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR |
POR | deletion | Frame_Shift_Del | novel | c.1514_1524delAGAACGGCGGC | p.Glu505AlafsTer66 | p.E505Afs*66 | P16435 | protein_coding | | | TCGA-AC-A8OQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
POR | deletion | In_Frame_Del | | c.443_445delNNN | p.Thr149del | p.T149del | P16435 | protein_coding | | | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
POR | SNV | Missense_Mutation | rs367782552 | c.773C>T | p.Ala258Val | p.A258V | P16435 | protein_coding | tolerated(0.29) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
POR | SNV | Missense_Mutation | novel | c.1897N>T | p.Gly633Trp | p.G633W | P16435 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A9U6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5447 | POR | ENZYME, DRUGGABLE GENOME | | sirolimus | SIROLIMUS | 23974086 |
5447 | POR | ENZYME, DRUGGABLE GENOME | | midazolam | MIDAZOLAM | 23324807,19801957 |
5447 | POR | ENZYME, DRUGGABLE GENOME | | cyclosporine | CYCLOSPORINE | 29135906,24658827,24061445 |
5447 | POR | ENZYME, DRUGGABLE GENOME | | zidovudine | ZIDOVUDINE | 22960662 |
5447 | POR | ENZYME, DRUGGABLE GENOME | | atorvastatin | ATORVASTATIN | 25521355 |
5447 | POR | ENZYME, DRUGGABLE GENOME | | nicotine | NICOTINE | |
5447 | POR | ENZYME, DRUGGABLE GENOME | | tacrolimus | TACROLIMUS | 23097010,25322286,26829596,30323313,24113216,26227094,21770725,24921414,24739669,25271728,24061445,28094348,29878980,29399716 |
5447 | POR | ENZYME, DRUGGABLE GENOME | | sunitinib | SUNITINIB | 28117434 |